For clinical laboratory directors, pharmaceutical R&D executives, healthcare investors, and strategic decision-makers evaluating the genomic medicine landscape, the transformation of gene sequencing from a specialized research tool to a mainstream clinical diagnostic platform represents one of the most significant advances in modern medicine. Traditional single-gene testing, while valuable for specific inherited conditions, cannot provide the comprehensive genomic insight required for complex disease risk assessment, targeted therapy selection, and population-scale screening programs. Gene sequencing equipment and services address this gap through technologies that enable rapid, cost-effective analysis of entire genomes, exomes, or targeted gene panels—unlocking actionable insights for cancer treatment, rare disease diagnosis, reproductive health, and pharmacogenomics. As sequencing costs have declined from over US$ 10 million for a human genome in 2007 to under US$ 1,000 today, clinical adoption has accelerated across oncology, prenatal screening, and inherited disease testing. Understanding the market dynamics, technology generations, and application-specific requirements of gene sequencing equipment and services becomes essential for stakeholders across the precision medicine value chain.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Gene Sequencing Equipment and Service – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Gene Sequencing Equipment and Service market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Gene Sequencing Equipment and Service was estimated to be worth US$ 2314 million in 2024 and is forecast to a readjusted size of US$ 4265 million by 2031 with a CAGR of 9.3% during the forecast period 2025-2031.
Gene sequencing is a new type of gene detection technology that can analyze and determine the complete sequence of genes from blood or saliva, predict the possibility of suffering from a variety of diseases, and individual behavior characteristics and behaviors are reasonable. Gene sequencing technology can lock individual disease genes, prevent and treat them in advance. Gene sequencing-related products and technologies have evolved from laboratory research to clinical use. It can be said that gene sequencing technology is the next technology that will change the world.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4031659/gene-sequencing-equipment-and-service
Market Size and Growth Fundamentals: A High-Growth Sector Powering Genomic Medicine
According to QYResearch’s comprehensive market assessment, the global gene sequencing equipment and service market was valued at US$ 2,314 million in 2024, with projected growth to US$ 4,265 million by 2031, representing a compound annual growth rate (CAGR) of 9.3% during the forecast period. This robust growth trajectory reflects the accelerating clinical adoption of sequencing technologies, the expansion of research applications across pharmaceutical development and academic discovery, and the continuous reduction in sequencing costs that enables broader utilization. The expansion is underpinned by three converging drivers: the increasing integration of genomic testing into standard oncology care for targeted therapy selection and minimal residual disease monitoring; the expansion of non-invasive prenatal testing (NIPT) and carrier screening programs; and the growing adoption of population-scale genomic screening initiatives across national healthcare systems.
Technology Architecture: Second-Generation, Third and Fourth Generation Sequencing
A critical dimension of market analysis involves understanding the technical distinctions among sequencing technology generations, each with distinct performance characteristics, cost structures, and application suitability.
Second-Generation Sequencing (Next-Generation Sequencing) represents the dominant technology segment, enabling massively parallel sequencing of millions of DNA fragments simultaneously. Second-generation platforms—led by Illumina’s sequencing-by-synthesis technology—achieve the lowest cost per base, making them the preferred choice for whole-genome sequencing, whole-exome sequencing, and large-scale population studies. These platforms deliver high accuracy (99.9%+) and are optimized for applications requiring comprehensive genomic coverage across hundreds or thousands of samples.
Third and Fourth Generation Sequencing encompasses long-read and real-time sequencing technologies that enable analysis of genomic regions inaccessible to short-read platforms. Third-generation platforms, including Pacific Biosciences’ single-molecule real-time (SMRT) sequencing and Oxford Nanopore’s nanopore sequencing, deliver read lengths exceeding tens of kilobases, enabling accurate assembly of complex genomic regions, detection of structural variants, and direct detection of epigenetic modifications. These technologies are increasingly specified for de novo genome assembly, repeat expansion disorders, and comprehensive structural variant analysis where short-read platforms are limited.
First-Generation Sequencing (Sanger sequencing) represents the established technology for low-throughput applications requiring high accuracy on individual amplicons. While first-generation sequencing accounts for a declining share of total sequencing output, it remains essential for validation studies, single-gene testing, and applications where rapid turnaround on limited samples is required.
Application Landscape: Academic Research, Clinical Research, Hospital Clinic, and Pharmaceutical Applications
The gene sequencing equipment and service market serves four primary application segments: academic research, clinical research, hospital clinic, and pharmaceutical and biotechnology.
Academic Research represents the largest application segment, encompassing basic biological research, population genetics, and disease mechanism studies. Academic sequencing demand is characterized by diverse applications, large-scale projects, and continuous technology adoption as costs decline.
Hospital Clinic represents the fastest-growing segment, driven by the integration of genomic testing into routine patient care. Clinical applications include oncology (tumor profiling, liquid biopsy, hereditary cancer risk), reproductive health (NIPT, carrier screening), rare disease diagnosis, and pharmacogenomics. The clinical segment is characterized by regulatory requirements, reimbursement considerations, and the need for certified laboratory infrastructure.
Pharmaceutical and Biotechnology applications encompass drug discovery, clinical trial biomarker identification, and companion diagnostic development. Pharmaceutical adoption of sequencing is accelerating as targeted therapies increasingly require companion diagnostics for patient selection.
Competitive Landscape: Global Leaders and Technology Innovators
The gene sequencing equipment and service market is characterized by a competitive landscape dominated by Illumina in the second-generation segment, with emerging challengers in long-read and nanopore technologies. Key participants include Illumina, Thermo Fisher Scientific, Eurofins Scientific, BGI, Natera, Berry, Roche, Novogene, MGI-tech, LabCorp, Pacific Biosciences, Azenta Life Sciences, Oxford Nanopore, and Macrogen.
Strategic Implications for Industry Stakeholders
For clinical laboratory directors and healthcare system executives, the strategic imperative is developing sequencing capabilities that align with institutional clinical priorities and patient populations. Platform selection must balance throughput requirements, cost per sample, and regulatory compliance considerations.
For pharmaceutical and biotechnology companies, sequencing partnerships enable biomarker discovery, patient stratification for clinical trials, and companion diagnostic development.
For investors, the gene sequencing equipment and service market represents exposure to precision medicine adoption, declining sequencing costs, and expanding clinical applications. The projected 9.3% CAGR through 2031 reflects sustained growth, with particular opportunities in clinical diagnostics and long-read sequencing technologies.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
